Singapore Institute of Advanced Medicine (SGX:9G2) trimmed its net attributable loss to equity holders from continuing operations in fiscal first half ended Dec. 31, 2025 to SG$11.6 million from SG$12.6 million a year earlier, according to a Friday filing with the Singapore Exchange.
Loss per share came in at SG$0.0104 compared with SG$0.0135 in the year-ago period.
Revenue inched up 3% year over year to SG$8.3 million from SG$8.0 million.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.